	US 12,343,364 B2
	Lactobacillus reuteri GMNL-263 for improving hypertension and its compositions thereof
Yi-Hsing Chen, Tainan (TW); and Wan-Hua Tsai, Kaohsiung (TW)
Assigned to GENMONT BIOTECH INCORPORATION, Tainan (TW)
Filed by GenMont Biotech Incorporation, Tainan (TW)
Filed on Dec. 15, 2021, as Appl. No. 17/552,187.
Application 17/552,187 is a continuation in part of application No. 16/018,338, filed on Jun. 26, 2018, abandoned.
Prior Publication US 2022/0105141 A1, Apr. 7, 2022
Int. Cl. A61K 35/747 (2015.01); A61P 9/12 (2006.01); C12N 1/20 (2006.01); A61K 35/745 (2015.01)

CPC A61K 35/747 (2013.01) [A61P 9/12 (2018.01); C12N 1/205 (2021.05); A61K 35/745 (2013.01)]

5 Claims

1. A method for treating hypertension in an individual, comprising administering to the individual a composition comprising a therapeutically effective amount of Lactobacillus reuteri GMNL-263 with the deposition number CCTCC M209263; wherein the individual suffers from hypertension; wherein the therapeutically effective amount is 2×10¹⁰CFUs of dead Lactobacillus reuteri GMNL-263 per day; wherein the therapeutically effective amount of 2×10¹⁰CFUs of dead Lactobacillus reuteri GMNL-263 does not significantly affect blood lipid levels of the individual, wherein the individual is not living with obesity.